Cumberland Pharmaceuticals (CPIX) EBIT Margin (2016 - 2025)
Historic EBIT Margin for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Q3 2025 value amounting to 23.7%.
- Cumberland Pharmaceuticals' EBIT Margin fell 50500.0% to 23.7% in Q3 2025 from the same period last year, while for Sep 2025 it was 7.9%, marking a year-over-year increase of 213700.0%. This contributed to the annual value of 16.99% for FY2024, which is 71700.0% up from last year.
- Per Cumberland Pharmaceuticals' latest filing, its EBIT Margin stood at 23.7% for Q3 2025, which was down 50500.0% from 6.9% recorded in Q2 2025.
- Cumberland Pharmaceuticals' 5-year EBIT Margin high stood at 11.03% for Q1 2025, and its period low was 66.07% during Q4 2023.
- Over the past 5 years, Cumberland Pharmaceuticals' median EBIT Margin value was 17.65% (recorded in 2024), while the average stood at 17.73%.
- In the last 5 years, Cumberland Pharmaceuticals' EBIT Margin crashed by -411000bps in 2023 and then skyrocketed by 484100bps in 2024.
- Cumberland Pharmaceuticals' EBIT Margin (Quarter) stood at 52.33% in 2021, then surged by 52bps to 24.97% in 2022, then crashed by -165bps to 66.07% in 2023, then surged by 73bps to 17.65% in 2024, then tumbled by -34bps to 23.7% in 2025.
- Its EBIT Margin stands at 23.7% for Q3 2025, versus 6.9% for Q2 2025 and 11.03% for Q1 2025.